Determination of foscarnet (trisodium phosphonoformate) in pharmaceutical preparations by high-performance liquid chromatrography with ultraviolet detection

Biomedical Chromatography

Volumn 20, Issue 10, 2006, Pages 1024-1027

  Garía, Javier ^a   Márquez, Apolonia ^b   Ruiz, Rosa ^c   López, Luis F ^c   Claro, Carmen ^a   Lucero, María Jesús ^a,d  

^a UNIVERSITY OF SEVILLE   (Spain)

^b HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^d NONE   (Spain)

Author keywords

Antiviral agent; Foscarnet; Isoosmotic sodium chloride solution; Trisodium phosphonophormate

Indexed keywords

ANTIVIRAL AGENTS; CHROMATOGRAPHIC ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SULFUR COMPOUNDS;

FOSCARNET; ISOCRATIC; ISOOSMOTIC SODIUM CHLORIDE SOLUTION; PERFORMANCE; PHARMACEUTICAL PREPARATIONS; SODIUM CHLORIDE SOLUTION; TRISODIUM PHOSPHONOPHORMATE; ULTRA VIOLET DETECTION; ULTRAVIOLET DETECTION; UV DETECTION;

SODIUM CHLORIDE;

FOSCARNET SODIUM; HYDROCHLOROTHIAZIDE;

ACCURACY; ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG ISOLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; QUANTITATIVE ANALYSIS; SENSITIVITY AND SPECIFICITY; ULTRAVIOLET RADIATION; VALIDATION PROCESS;

EID: 33750709277     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.629     Document Type: Article

References (26)

1. Alvarez C, Gömez JL, Martínez R, Souto C and Concheiro A. Microviscosity of hydroxypropylcellulose gels as a basis for prediction of drug diffusion rates. International Journal of Pharmacy 1999; 180: 91.
2. Alvarez C, Duro, F, Gómez JL, Martínez R, Souto C and Concheiro A. Influence of polymer structure on the rheological behavior of hydroxypropylmethylcellulose-sodium carboxymethyl-cellulose dispersions. Colloid Polymer Science 2001; 279: 1045.
3. Balfour HH. Drug therapy: antiviral drugs. New England Journal of Medicine 1999; 340: 1255.
4. Barreiro R, Alvarez C and Concheiro A. Incorporation of small quantities of surfactants as a way to improve the rheological and diffusional behavior of carbopol gels. Journal of Control Release 2001; 77: 59.
5. Bernstein DI, Ireland J and Bourne N. Pathogenesis of acyclovir-resistant herpes simplex type 2 isolates in animal models of genital herpes: model form antiviral evaluations. Antiviral Research 2000; 47:159.
6. Bundgaard H and Mork N. Kinetics of the decarboxylation of foscarnet in acidic aqueous solution and its implication in its oral absorption. International Journal of Pharmacy 1990; 63: 213.
7. Forsman U, Andersson M and Tornros H. Ion-exchange chromatography with post-column reaction for the analysis of phosphonoformate phosphite and phosphate. Journal of Chromatography 1986; 369: 151.
8. García J. Diseño de sistemas dispersos de HPMC y Eudragit® para la liberación tópica de foscarnet. Doctoral Thesis. University of Seville. 2003.
9. Gilbert C, Bestman-Smith J and Boivin G. Resistance of herpesviruses to antiviral drugs: clinical impacts and molecular mechanisma. Drug Resistance Updates 2002; 5: 88.
10. Haefelfinger P. Limits of the internal standard technique in chromatography. Journal of Chromatography 1981; 218: 73.
11. Hassanzadeh MK, Aweeka FT, Wu S, Jacobson MA and Gambertoglio JG. Determination of phosphonoformic acid in human plasma and urine by high-performance liquid chromatography with electrochemical detection. Journal of Chromatography 1990; 525: 133.
12. López LF, Ruiz R, Lucero MJ, Cordero E, Pastor MT and Marquez J. Intravitreal, retinal, and central nervous system foscarnet concentrations after rapid intravenous administration to rabbits. Anti-microbial Agents and Chemotherapy 2000; 44: 756.
13. López LF, Pastor MT, Ruiz R, Cordero E, Uceda A, Claro C and Lucero MJ. Intravitreal pharmacokinetics and retinal concentrations of glanciclovir and foscarnet after intravitreal administration in rabbits. Investigative Ophthalmology and Visual Science 2001; 42: 1024.
14. Ministerio de Sanidad. Real Farmacopea Española, 2nd edn. Ministerio de Sanidad: Madrid, 2002; 1465.
15. Morfin F and Thouvenot D. Herpes simplex virus resistance to antiviral drugs. Journal of Clinical Virology 2003; 26: 29.
16. Öberg B. Antiviral effect of phosphonoformate (PFA, foscarnet sodium). Pharmacological Therapy 1989; 40: 213.
17. Pettersson KJ, Nordgren T and Westerlund D. Determination of phosphonoformate (foscarnet) in biological fluids by ion-pair reversed-phase liquid chromatography. Journal of Chromatography 1989; 488: 447.
18. Piret J, Courde P, Cormier H, Désormeaux A, Beauchamp D, Tremblay MJ, Juhász J and Bergeron. MG. Efficacy of gel formulations containing free and liposomal foscarnet in a murine model of cutaneous HSV-1 infection. Journal of Liposome Research 1999; 9: 181.
19. Piret J, Désormeaux A, Courde P, Juhász J and Bergeron MG. Efficacies of topical formulations of foscarnet and acyclovir and of 5-percent acyclovir ointment (Zovirax) in a murine model of cutaneous herpes simplex virus type 1 infection. Antimicrobial Agents and Chemotherapy 2000a; 44: 30.
20. Piret J, Désormeaux A, Cormier H, Lamontagne J, Courde P, Juhász J and Bergeron MG. Sodium lauryl sulfate increases the efficacy of a topical formulation of foscarnet against herpes simplex virus type 1 cutaneous lesions in mice. Antimicrobial Agents and Chemotherapy 2000b; 44: 2263.
21. Riley CM, Ault JM and Klutman NE. Chromatographic methods for the bioanalysis of antiviral agents. Journal of Chromatography B 1990; 531: 295.
22. Ringden O, Lonnqvist B, Paulin T, Ahlmen J, Klintmalm G, Wahren B and Lernestedt JO. Pharmacokinetics, safety and preliminary clinical experiences using, foscarnet in the treatment of cytomegalovirus infections in bone marrow and renal transplant recipients. Journal of Antimicrobial Chemotherapy 1986; 17: 373.
23. Sall RK, Kauffman CL and Levy CS. Successful treatment of progressive acyclovir-resistant herpes simplex virus using intravenous foscarnet in a patient with the acquired immunodeficiency syndrome. Archives of Dermatology 1989; 125: 1548.
24. Sandstrom EG, Kaplan JC, Byington RE and Hirsch MS. Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate. Lancet 1985; 1: 1480.
25. Spruance SL and Freeman DJ. Topical treatment of cutaneous herpes simplex infections. Antiviral Research 1990; 14: 305.
26. Woods K, Steinmann W, Bruns L and Neels JT. Stability of foscarnet sodium in 0.9% sodium chloride injection. Americal Hospital Pharmacy 1994, 51: 88.